Highlights Propanc Biopharma, Inc.

Equities

PPCB

US74346N6022

Delayed OTC Markets Other stock markets 07:56:40 15/05/2024 pm IST			5-day change	1st Jan Change
0.00078 ^USD	-13.33%		-46.67%	-93.33%

16/04	Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office	CI
16/04	Propanc Biopharma, Inc. announced that it has received $0.025 million in funding from GS Capital Partners LLC	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office	16/04	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	21/02	CI
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office	16/01	CI
Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	15/11	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	29/23/29	CI
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia	15/23/15	CI
Propanc Biopharma, Inc. Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors	05/23/05	CI
Propanc Biopharma, Inc. Announces Strategic Pharma Partnering Initiative	06/23/06	CI
Propanc Biopharma, Inc.'s Intellectual Property Portfolio Makes Important Advancements in Europe	25/23/25	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	16/23/16	CI
Propanc Biopharma, Inc. Announces That PRP Suppresses TGF-b Pathway & Tumor Microenvironment in Pancreatic Cancer	28/23/28	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	10/23/10	CI
Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer	15/22/15	CI
Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	15/22/15	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	29/22/29	CI
Propanc Biopharma, Inc. Synthesizes Recombinant Trypsinogen & Chymotrypsinogen Via Proenzyme Optimization Project Joint Research & Drug Discovery Program	23/22/23	CI
Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office	16/22/16	CI
Propanc Biopharma, Inc. Establishes Joint Research Collaboration Agreement with the Universities of Jaén and Granada	03/22/03	CI
Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered over Past Decade	28/22/28	CI
Propanc Biopharma, Inc. Successfully Produces Synthetic Recombinant Trypsinogen Via POP1 Joint Research & Drug Discovery Program	19/22/19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Propanc Biopharma, Inc.

Equities

PPCB

US74346N6022

Highlights

Filters